Layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired by Gilead Sciences and Novartis, respectively.
Biopharma professionals sometimes find themselves out of jobs when employers want to bring staff back into the office, as recently seen at biotech EMD Serono and Exelixis.
Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people.
Job postings increase and competition dips, according to BioSpace data.
Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.
In addition to laying off employees, including a member of its management team, Lisata Therapeutics is also suing Kuva Labs, alleging the company breached a merger agreement.
Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”
So far in 2026, over 50 biopharmas have cut or plan to cut their workforces. If they didn’t take a careful, thoughtful approach to telling people they were being laid off, they likely left a negative impression on employees, based on stories shared with BioSpace.
PRESS RELEASES
